Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Phase 1 Study of Tabalumab, a Human Anti-BAFF Antibody and Bortezomib in Patients with Previously-Treated Multiple Myeloma

Noopur Raje, MD, Edward Anthony Faber, Jr., DO, MS, Paul G. Richardson, MD, Gary J. Schiller, MD, Raymond J. Hohl, MD, PhD, Adam D. Cohen, MD, Andres Forero, MD, Susan P. Carpenter, PhD, Damien Cronier, PhD, Christopher Kaiser, PhD, James E. Wooldridge, MD, Kenneth C. Anderson, MD

Blood (2012) 120 (21): 447.

https://doi.org/10.1182/blood.V120.21.447.447

Published: 2012

Journal Articles

Sustained Depletion of B-Cells by a Humanized, Fc-Engineered Anti-CD20 Antibody, AME-133v, in Patients with Relapsed Follicular Lymphoma

Jennifer Wayne, MS, Kristen N. Ganjoo, MD, Andres Forero, MD, Brad Pohlman, MD, Sven de Vos, MD, PhD, Susan P. Carpenter, PhD, James E Wooldridge, MD, Shashidhara Marulappa, DVM, MVSc, MBA, Vinay Jain, MBBS, MD, FACP

Blood (2011) 118 (21): 4977.

https://doi.org/10.1182/blood.V118.21.4977.4977

Published: 2011

Journal Articles

Genetic Polymorphisms In Genes Involved In R-CHOP Metabolism and Event-Free and Overall Survival In Diffuse Large B-Cell Lymphoma

James R Cerhan, MD, PhD, Thomas M Habermann, MD, Matthew J Maurer, MS, James E Wooldridge, MD, Stephen M Ansell, MD, PhD, Grzegorz S. Nowakowski, MD, Ivana N Micallef, MD, Carrie A Thompson, MD, Alice H Wang, BA, William R Macon, MD, Sergei I Syrbu, MD, Susan L Slager, PhD, Thomas E Witzig, MD, Brian Link

Blood (2010) 116 (21): 996.

https://doi.org/10.1182/blood.V116.21.996.996

Published: 2010

Journal Articles

Phase I Study of a New Humanized Anti-CD20 Monoclonal Antibody (LY2469298) in Japanese Patients (pts) with Relapsed or Refractory Follicular Lymphoma (FL) Pretreated with Rituximab-Containing Regimen

Michinori Ogura, MD, PhD, Kensei Tobinai, MD, PhD, Toshiki Uchida, MD, PhD, Yukio Kobayashi, MD, PhD, Takashi Oyama, MD, Takashi Watanabe, MD, PhD, Tatsuya Suzuki, MD, PhD, Dai Maruyama, MD, PhD, Masanobu Kasai, MD, Masakazu Mori, MD, Tomomi Matsue, Damien Cronier, PhD, James E Wooldridge, MD, Minori Koshiji, MD, PhD

Blood (2010) 116 (21): 3942.

https://doi.org/10.1182/blood.V116.21.3942.3942

Published: 2010

Journal Articles

Oral Tipifarnib (R115777) Has Single Agent Anti-Tumor Activity in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma (NHL): Results of a Phase II Trial in the University of Iowa/Mayo Clinic Lymphoma SPORE (CA97274).

Thomas E. Witzig, MD, Matthew J. Maurer, Patrick B. Johnston, MD, Joseph P. Colgan, MD, Scott H. Kaufmann, MD, PhD, David J. Inwards, MD, Ivana N. Micallef, MD, Stephen M. Ansell, MD, PhD, Clive S. Zent, MD, Cristine Allmer, George J. Weiner, MD, James E. Wooldridge, MD, Brian K. Link, MD, Thomas M. Habermann, MD

Blood (2006) 108 (11): 530.

https://doi.org/10.1182/blood.V108.11.530.530

Published: 2006

Journal Articles

IL-21 Plus CpG ODN Induces Granzyme B-Dependent Induction of Apoptosis in CD5-Positive B Cells Including B-CLL Cells.

Sue E. Blackwell, Bernd Jahrsdoerfer, MD, James E. Wooldridge, MD, Jian Huang, Melinda W. Andreski, Laura S. Jacobus, Christiana M. Taylor, George J. Weiner, MD

Blood (2006) 108 (11): 2823.

https://doi.org/10.1182/blood.V108.11.2823.2823

Published: 2006

Journal Articles

Anti-CD20 Monoclonal Antibody (mAb) with Enhanced Affinity for CD16 Activates NK Cells at Lower Concentrations and More Effectively Than Rituximab ®.

George J. Weiner, MD, Julie A. Bowles, BS, Brian K. Link, MD, Mary A. Campbell, PhD, James E. Wooldridge, MD, James B. Breitmeyer, MD, PhD

Blood (2005) 106 (11): 348.

https://doi.org/10.1182/blood.V106.11.348.348

Published: 2005

Journal Articles

IL-21 and CpG ODN Are Synergistic in Their Ability To Induce Apoptosis of Chronic Lymphocytic Leukemia (CLL) Cells and Benign B1 Cells.

Bernd Jahrsdoerfer, MD, Sue E. Blackwell, James E. Wooldridge, MD, Melinda W. Andreski, Laura S. Jacobus, Christiana M. Taylor, George J. Weiner, MD

Blood (2005) 106 (11): 5022.

https://doi.org/10.1182/blood.V106.11.5022.5022

Published: 2005

Journal Articles

A Polymorphism in the C1qA Component of Complement Correlates with Prolonged Complete Remission Following Rituximab Therapy of Follicular Lymphoma.

Emilian Racila, MD, Wen-Kai Weng, MD, James E. Wooldridge, MD, Brian K. Link, MD, Ronald Levy, MD, George J. Weiner, MD

Blood (2005) 106 (11): 778.

https://doi.org/10.1182/blood.V106.11.778.778

Published: 2005

Journal Articles

FDG PET Scan Alone Better Predicts Progression Free Survival at 2 Years Compared to CT Imaging in Aggressive Histology Non-Hodgkin’s Lymphoma Following Initial Anthracycline-Based Chemotherapy.

Gregory A. Wiseman, MD, Malik E. Juweid, MD, Eric M. Rohren, MD, PhD, James E. Wooldridge, MD, Michael M. Graham, MD, PhD

Blood (2004) 104 (11): 3299.

https://doi.org/10.1182/blood.V104.11.3299.3299

Published: 2004

Journal Articles

Incidence of Febrile Neutropenia Is Low and Unrelated to Day 1 Neutrophil Count in Hodgkin’s Lymphoma Treated with ABVD.

Vikram K. Chand, MBBS, Justine Ritchie, PhD, Mary Shannon, RN, BSN, Brian K. Link, MD, James E. Wooldridge, MD

Blood (2004) 104 (11): 4590.

https://doi.org/10.1182/blood.V104.11.4590.4590

Published: 2004

Journal Articles

Cpg Oligodeoxynucleotide-Mediated Effects on B-Cell Chronic Lymphocytic Leukemia In Vitro Are Influenced by Cytogenetic Status and the Presence of Serum.

Bernd Jahrsdorfer, MD, Sue E. Blackwell, James E. Wooldridge, MD, Christiana M. Taylor, George J. Weiner, MD

Blood (2004) 104 (11): 4828.

https://doi.org/10.1182/blood.V104.11.4828.4828

Published: 2004

NARROW

Phase 1 Study of Tabalumab, a Human Anti-BAFF Antibody and Bortezomib in Patients with Previously-Treated Multiple Myeloma

Sustained Depletion of B-Cells by a Humanized, Fc-Engineered Anti-CD20 Antibody, AME-133v, in Patients with Relapsed Follicular Lymphoma

Genetic Polymorphisms In Genes Involved In R-CHOP Metabolism and Event-Free and Overall Survival In Diffuse Large B-Cell Lymphoma

Phase I Study of a New Humanized Anti-CD20 Monoclonal Antibody (LY2469298) in Japanese Patients (pts) with Relapsed or Refractory Follicular Lymphoma (FL) Pretreated with Rituximab-Containing Regimen

Oral Tipifarnib (R115777) Has Single Agent Anti-Tumor Activity in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma (NHL): Results of a Phase II Trial in the University of Iowa/Mayo Clinic Lymphoma SPORE (CA97274).

IL-21 Plus CpG ODN Induces Granzyme B-Dependent Induction of Apoptosis in CD5-Positive B Cells Including B-CLL Cells.

Anti-CD20 Monoclonal Antibody (mAb) with Enhanced Affinity for CD16 Activates NK Cells at Lower Concentrations and More Effectively Than Rituximab ®.

IL-21 and CpG ODN Are Synergistic in Their Ability To Induce Apoptosis of Chronic Lymphocytic Leukemia (CLL) Cells and Benign B1 Cells.

A Polymorphism in the C1qA Component of Complement Correlates with Prolonged Complete Remission Following Rituximab Therapy of Follicular Lymphoma.

FDG PET Scan Alone Better Predicts Progression Free Survival at 2 Years Compared to CT Imaging in Aggressive Histology Non-Hodgkin’s Lymphoma Following Initial Anthracycline-Based Chemotherapy.

Incidence of Febrile Neutropenia Is Low and Unrelated to Day 1 Neutrophil Count in Hodgkin’s Lymphoma Treated with ABVD.

Cpg Oligodeoxynucleotide-Mediated Effects on B-Cell Chronic Lymphocytic Leukemia In Vitro Are Influenced by Cytogenetic Status and the Presence of Serum.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only